At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Standard of Care (other)
- How long the study runs
- Study runs about 174 months (dates as stated)
- About the drug or intervention
- Standard of Care — other: Drugs routinely administered for metastatic prostate cancer per local standard.
- Patient visit burden
- Not specified by the sponsor
In plain English
IRONMAN is an international registry collecting information from men with advanced prostate cancer. A registry gathers health details over time to help researchers learn more about the condition. It is run by the Prostate Cancer Clinical Trials Consortium.
Who can take part
- Men aged 21 or over.
- Willing and able to give written permission (consent) and agree to share your personal health information.
- Prostate cancer confirmed by tissue tests, or cancer that has spread in a pattern typical of prostate cancer (such as to bone or nearby lymph nodes) together with a high blood PSA (prostate-specific antigen) level above 20 ng/mL when first diagnosed.
Who may not be able to
- Men who have been diagnosed with another cancer, other than prostate cancer, that needs further treatment. Exceptions are non-invasive bladder cancer and a common skin cancer called basal cell cancer.
What taking part involves
- • Not stated — ask the trial team.
Time commitment: Not stated — ask the trial team about what taking part involves, how long it lasts, and how often you would be seen.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- 21 Years and over
- Who
- Male
- Number of participants
- 5,000
- Started
- 2017-07-21
- Last checked
- 2026-05
Plain English Summary
What is this study?
- • Testing a new treatment for prostate cancer
- • Clinical study - 5,000 participants
- • Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC
Who can take part?
- • Ages 21 Years and over
- • Diagnosed with prostate cancer
- • Male only
Where?
- • Southampton - University Hospital Southampton NHS Foundation Trust
- • Stevenage - Lister Hospital
- • Northwood - Mount Vernon Cancer Centre
- • Cardiff - Velindre Cancer Centre
- • +9 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingdom (UK), and the United States (US). Target accrual number and number of participating sites are subject to change based on accrual, funding, and interest in participation by other international sites. This cohort study will facilitate a better understanding of the variation in care and treatment of advanced prostate cancer across countries and across academia and community based practices. Detailed data will be collected from patients at study enrollment and then during follow-up, for a minimum of five years. Patients will be followed prospectively for overall survival, clinically significant adverse events, comorbidities, changes in cancer treatments, and PROMs. PROMs questionnaires will be collected at enrollment and every three months thereafter. Physician Questionnaires will be collected from all participating sites at patient enrollment, time of first change in treatment and/or one year follow-up, at each subsequent change of treatment, and discontinuation of treatment. As such, this registry will help identify the treatment sequences or combinations that optimize overall survival and PROMs for men with mHSPC and M0/M1 CRPC. By collecting blood at enrollment, time of first change in treatment and/or one year follow-up (plasma, cell free DNA, buffy coat / RNA), this registry will further identify and validate molecular phenotypes of disease that predict response and resistance to specific therapeutics. Additionally, every effort will be made to collect blood specimen at each subsequent change in treatment due to progression of disease. When feasible, existing tumor tissue may be collected for correlation with described blood based studies. All samples will be used for future research. This cohort study will provide the research community with a unique biorepository to identify biomarkers of treatment response and resistance.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 21 Years and over
- Who can join: Male only
Biomarkers mentioned
Treatment history
Treatments you must have had:
- ✓ additional systemic therapy except cancer in situ of bladder and basal cell cancer of skin
What the study is looking for
- ✓Willing and able to provide written agreement to take part and privacy authorization for the release of personal health...
- ✓NOTE: Privacy authorization may be either included in the agreement to take part or obtained separately.
- ✓Males 21 years of age and above
- ✓No previous diagnosis of a second, non-prostate cancer that requires additional treatment that goes through your whole body except cancer...
See the full criteria
Where Is This Study? (13 UK sites)
University Hospital Southampton NHS Foundation Trust
Southampton, United Kingdom
Lister Hospital
Stevenage SG1 4AB, United Kingdom
Mount Vernon Cancer Centre
Northwood HA6 2RN, United Kingdom
Velindre Cancer Centre
Cardiff, United Kingdom
University Hospitals of Morecambe Bay NHS Foundation Trust
Lancaster, United Kingdom
Guys St Thomas NHS Foundation Trust
London, United Kingdom
The Royal Marsden NHS Foundation Trust
London, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
Clatterbridge Cancer Centre
Metropolitan Borough of Wirral, United Kingdom
Lancashire Teaching Hospitals NHS Foundation Trust
Preston PR2 9HT, United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield S10 2SB, United Kingdom
South Tyneside District Hospital
South Shields NE34 0PL, United Kingdom
Research and Development stsft.research@nhs.net
stsft.research@nhs.net0191 565 6256 ext 42143Sunderland Royal Hospital
Sunderland SR4 7TP, United Kingdom
How to Get in Touch
Jacob Vinson
Sponsor contactCONTACT